Proportion of patients responding according to EULAR classification to switching to rituximab compared with switching to alternative TNF antagonists after propensity score stratification
| 6 months | 9 months | 12 months | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Good | Moderate | No response | Good | Moderate | No response | Good | Moderate | No response | |
| Rituximab | 59 | 15 | 26 | 51 | 22 | 27 | 64 | 18 | 18 |
| TNF antagonists | 45 | 20 | 35 | 56 | 20 | 24 | 60 | 16 | 24 |
| p Value | 0.025 | 0.43 | 0.46 | ||||||
TNF, tumour necrosis factor.